FindTrial
Sign In

The Dose-response study of Bupivacaine for Cesarean Section under Combined spinal-epidural Anesthesia when Prophylactic Infusion of Phenylephrine

The Dose-response study of Bupivacaine for Cesarean Section under Combined spinal-epidural Anesthesia when Prophylactic Infusion of Phenylephrine

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008938
Enrollment
Unknown
Registered
2016-07-28
Start date
2016-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

parturients

Interventions

Group 10 mg:intravenous infusion phenylephrine
Group 9 mg:intravenous infusion phenylephrine
Group 8 mg:intravenous infusion phenylephrine
Group 7 mg:intravenous infusion phenylephrine
Group 6 mg:intravenous infusion phenylephrine

Sponsors

Jiaxing Maternity and Child Care Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: The full-term healthy primipara

Exclusion criteria

Exclusion criteria: Any contraindication to combined spinal-epidural anesthesia (CSEA), body mass index greater than 35 kg/m2, chronic hypertension, coagulation abnormality, platelet count less than 75*10^9/L, local or generalized sepsis, cord prolapsed, gestation less than 28 weeks, twin pregnancy, active labor, high-risk pregnancy, patients age less than 25 years old or more than 40 years old, patients height less than 150 cm or more than 170 cm, a nonreassuring fetal heart rate, or a suspected fetal pathology.

Design outcomes

Primary

MeasureTime frame
ED50 and ED95;ED50 and ED95;—

Countries

China

Contacts

Public ContactFEI XIAO

Jiaxing Maternity and Child Care Hospital

13706597501@163.com+86 13706597501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026